News About: Pharm. Industry
The strong of OTC drugs, Dongwha Pharm, expanded to CNS infections
The oldest company, Dongwha Pharm, has domestically acquired an approval for the new quinolones-type antibiotic for the third time after Factive and Q-Roxin.
On the last 20th, Dongwha has acquired a product approval ...
As the Patent Linkage System is enforced, pharmaceutical companies have continued to apply for lawsuits
Due to enforcement of the Patent Linkage System, it is known that pharmaceutical companies have shown active movements to meet the requirement for the very first lawsuit and the very first approval application.
Accor...
Green Cross vs Ildong Pharmaceutical, ‘would it be success of Green Cross or defense of Ildong Pharmaceutical?’The shareholders’ general meeting of Ildong Pharmaceutical (the 20th) has attracted attention of the pharmaceutical industry.
Triggered by the shareholder proposal of Green Cro...
|
Hanmi Pharm is developing the salt alteration product of Tamifly to avoid the patentHanmi Pharm has begun to develop the salt alteration product of the flu treatment, Tamiflu.
This is because it is trying to avoid the Roche’s salt patent for Tamiflu; the decis...
|
MSD, the developing company of simbastatin, will sell atorvastatin from the next month
MSD will launch the atorvastatin and ezetimibe hyperlipidemia complex ‘Atozet’ within the middle of the next month.
Atozet has been approved in 23 January 2015 and secured the base of the launch with the approval of ...
Hanmi Pharm has made a license contract of immunization disease treatments with LillyHanmi Pharm and Eli Lilly announced on the 19th that they have made a license and cooperation contract to develop and commercialize the Hanmi Pharm’s BTK inhibitor, HM71224, rel...
|
9 listed pharmaceutical companies have warning signals on in cash mobilizing power
It is analyzed that 9 listed pharmaceutical companies, such as Myungmoon Pharm, Dong-A Socio Holdings, Hanmi Science, have warning signals on in cash mobilizing power.
According to the YakupDotCom’s analysis result o...
Would the 2nd battle break out between Trajenta and Januvia due to the beneficiary standard alteration?
While Trajenta (generic name: linagliptin) is catching up, Januvia (generic name: sitagliptin) is running away; the two products dividing the DDP-4 inhibitor market are reviving its endless chase using the alteration ...
Stock price of Hanmi Pharm increased 65% up in a monthWould it be the precursor predicting the new drug project, titled ‘Quantum Jump’?
Stock price of Hanmi Pharm has significantly increased. The increase was 65% up in a month.
T...
|
Kunwha Pharmaceutical decided to merger ‘Dream Pharma’
The Kunwha Pharmaceutical’s merger with Dream Pharm has been decided.
Kunwha Pharmaceutical announced on the 17th that it decided to merger its 100% affiliated company, Dream Pharma Inc. (Kunwha Pharmaceutical owns 1...
